For these reasons, GH and IGF-1 could represent a novel strategy therapy in neurodegenerative diseases such as ALS, Alzheimer’s disease (AD), Parkinson, and dementia. This evidence concerns the gene GH1 and early-onset autosomal dominant Alzheimer disease.